Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Income from Non-Controlling Interests (2020 - 2025)

Historic Income from Non-Controlling Interests for aTYR PHARMA (ATYR) over the last 5 years, with Q3 2025 value amounting to -$2000.0.

  • aTYR PHARMA's Income from Non-Controlling Interests changed 0.0% to -$2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5000.0, marking a year-over-year decrease of 60000.0%. This contributed to the annual value of $1000.0 for FY2024, which is 11250.0% up from last year.
  • As of Q3 2025, aTYR PHARMA's Income from Non-Controlling Interests stood at -$2000.0, which was down 0.0% from -$1000.0 recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Income from Non-Controlling Interests registered a high of $4000.0 during Q1 2024, and its lowest value of -$4000.0 during Q2 2023.
  • In the last 4 years, aTYR PHARMA's Income from Non-Controlling Interests had a median value of -$1000.0 in 2022 and averaged -$1153.8.
  • As far as peak fluctuations go, aTYR PHARMA's Income from Non-Controlling Interests surged by 50000.0% in 2024, and later plummeted by 12500.0% in 2025.
  • Quarter analysis of 4 years shows aTYR PHARMA's Income from Non-Controlling Interests stood at -$2000.0 in 2022, then skyrocketed by 50.0% to -$1000.0 in 2023, then changed by 0.0% to -$1000.0 in 2024, then crashed by 100.0% to -$2000.0 in 2025.
  • Its last three reported values are -$2000.0 in Q3 2025, -$1000.0 for Q2 2025, and -$1000.0 during Q1 2025.